Parl Panel Moots One-Time Settlement of Drug Overpricing Cases

Published On 2016-05-01 05:10 GMT   |   Update On 2016-05-01 05:10 GMT

A Parliamentary panel has suggested a one-time settlement of drug overpricing cases that regulator NPPA is currently fighting with the pharmaceutical companies.


Drug price regulator National Pharmaceutical Pricing Authority (NPPA) has been trying to recover a whopping Rs 4,551 crore including interests from various pharma companies for overcharging as of February this year. As much as 82 per cent of this amount is under litigation.


The standing committee on Ministry of Chemicals and Fertilisers in its report tabled in Parliament noted that NPPA had prepared a draft for one-time settlement with an aim of quick recovery of overcharged amount that was sent to the Department of Pharmaceuticals for its formal approval.


"The earlier proposal sent two years back to Ministry of Finance was not approved. The committee, therefore recommend that the department should take up the matter with Ministry of Finance again by strongly putting its case for one-time settlement scheme with full justification," the report added.


The Parliamentary panel also said it is dismayed to note that since inception of NPPA, there are 1,389 cases as on February 29, 2016. Where demand notices have been issued to pharmaceutical companies for recovery of overcharged amount.


NPPA mandate is to fix or revise the prices of controlled bulk drugs, formulations and to enforce prices and availability of the medicines in the country. It has been entrusted with fixation of prices of scheduled drugs under the Drug (Price Control) Order, 1995 (DPCO) 1995 and DPCO 2013.


The regulator also monitors prices of decontrolled drugs in order to keep them at reasonable levels.

Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News